medigraphic.com

2022, Number 3

<< Back

Rev Hematol Mex 2022; 23 (3)

Atypical manifestation of systemic light chain amyloidosis and multiple myeloma in a patient post-COVID-19

González-Galván AC, González-Rosas IA

Language: Spanish
References: 12
Page: 230-235
PDF size: 293.91 Kb.


ABSTRACT

Background: The hypothesis of amyloid protein enhancement or overexpression in the presence of SARS-CoV-2 virus envelope proteins is associated with systemic amyloidosis as a secondary disease.
Clinical case: A 51-year-old female patient with atypical symptoms of systemic light chain amyloidosis, which progressed to heart failure with reduced LVEF and multiple myeloma after SARS-CoV-2 infection.
Conclusions:Although AL amyloidosis manifests in 15% with multiple myeloma, and the average manifestation is 6 months after the diagnosis of multiple myeloma, in advanced ages and predominantly in males, simultaneous manifestations are not ruled out in patients with previous SARS-CoV-2 infections, and with an adverse prognosis in severe heart disease, so early recognition is key to patient survival.


REFERENCES

  1. Jana AK, Greenwood AB, Hansmann UE. Presence ofa SARS-CoV-2 protein enhances amyloid formation ofserum amyloid A. bioRxiv 2021; 2021.05.18.444723. doi:10.1101/2021.05.18.444723.

  2. Galkin A. Hypothesis: AA amyloidosis is a factor causingsystemic complications after coronavirus disease. Prion2021; 15 (1): 53-55. doi: 10.1080/19336896.2021.1910468.

  3. Quock TP. Epidemiology of AL amyloidosis: a real-worldstudy using US claims data. Blood Adv 2018; 2 (10): 1046-1053. doi: 10.1182/bloodadvances.2018016402.

  4. Law S, Fontana M, Gillmore JD. Advances in diagnosis andtreatment of cardiac and renal amyloidosis. Cardiol Clin2021; 39 (3): 389-402. doi: 10.1016/j.ccl.2021.04.010.

  5. Stern LK, Kittleson MM. Updates in cardiac amyloidosisdiagnosis and treatment. Current Oncology Rep 2021; 23(4). doi:10.1007/s11912-021-01028-8

  6. Fotiou D, Dimopoulos MA, Kastritis E. Systemic ALamyloidosis: Current approaches to diagnosis and management.HemaSphere 2020; 4 (4): e454. doi:10.1097/hs9.0000000000000454.

  7. Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR,Zeldenrust SR, et al. Clinical features and treatmentresponse of light chain (AL) amyloidosis diagnosed in patientswith previous diagnosis of multiple myeloma. MayoClinic Proceedings 2010; 85 (3): 232-238. doi:10.4065/mcp.2009.0547.

  8. Semerdzhiev SA, Fakhree MAA, Segers-Nolten I, BlumC, Claessens MMAE. Interactions between SARSCoV-2 N proteinand-synuclein accelerate amyloidformation. bioRxiv 2021; 2021.04.12.439549. DOI:10.1101/2021.04.12.439549.

  9. Gertz MA. Immunoglobulin light chain amyloidosis: 2020update on diagnosis, prognosis, and treatment. Am J Hematol2020. doi:10.1002/ajh.25819

  10. Tomberli B, Cappelli F, Perfetto F, Olivotto I. Abrupt onset ofrefractory heart failure associated with light-chain amyloidosisin hypertrophic cardiomyopathy. JAMA Cardiol 2017;2 (1): 94. doi:10.1001/jamacardio.2016.389.

  11. Lee H, Tay J, Duggan P, McCulloch S, Neri P, Bahlis NJ,Jimenez-Zepeda VH. The impact of COVID-19 in the managementof AL amyloidosis and immunoglobulin depositiondisease: A single-center experience. Eur J Haematol 2020;106 (3): 340-345. doi:10.1111/ejh.13552.

  12. Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosiswith delayed progression to multiple myeloma.Cancer 1998; 82 (8): 1501-1505.




2020     |     www.medigraphic.com